Podocyte Adaptation Proliferation and Ageing

Información del proyecto

PAPAstudy

Identificador del acuerdo de subvención: 679254

DOI

10.3030/679254

Proyecto cerrado

Fecha de la firma de la CE 19 Febrero 2016

Fecha de inicio 1 Marzo 2016

Fecha de finalización 28 Febrero 2021

Financiado con arreglo a

• EXCELLENT SCIENCE - European Research Council (ERC)

Coste total

€ 1 479 260,00

Aportación de la UE

€ 1 479 260,00

Coordinado por

UNIVERSITE PARIS CITE
France

Periodic Reporting for period 4 - PAPAstudy (Podocyte Adaptation Proliferation and Ageing)

Período documentado: 2020-09-01 hasta 2021-02-28

Resumen del contexto y de los objetivos generales del proyecto

The PAPAstudy project aims at discovering new treatment for rare disorders involving the PIK3CA/AKT/mTOR pathway. Our goal is to offer to patients molecular targeted therapy. To this aim we are using complementary in vivo and in vitro approaches, innovative new technology of bioengineering and we develop genetically modified mouse models. We are located in the close vicinity of the clinical department allowing bed to beachside or vice et versa approaches.

This project has broken all the boundaries that were existing between different medical specialities and allowed the
rapid repurposing of a new drug undergoing development in oncology. This project is clearly considered by outside experts as a breakthrough discovery.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

Since the beginning of the project, we did develop a new way to isolate primary podocytes (our cells of interest) from mice and to grow them up in vitro. The podocyte is a highly specialized cell with foot processes expansion that function as vasculature-supporting cells, producing basement membrane components and a number of vascular growth factors. These cells play an essential role in renal physiology but their unique localization, as the primary filter, exposes them to many stresses in pathological conditions. In fact these cells are the direct target of many diseases such as diabetes or HIV. We are currently testing and developing various mouse models.

The project resulted in a patent application that has been filled in by the Université de Paris.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Using this method, we discovered promising treatment for other disorders such as mitochondrial diseases, antiphospholipid vasculopathy, CLOVES syndrome or other PIK3CA related overgrowth syndrome.

gcanaud.jpg